文献速递产科

联合治疗而非单用缩宫素预防产后出血

Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone.
PubMed 文献 · Am J Obstet Gynecol MFM · 2022-08-24

产后出血是全球孕产妇发病和死亡的首要原因,宫缩乏力约占70%至80%的病例。药物治疗仍是产后出血的一线预防手段,缩宫素为美国一线宫缩剂,卡贝缩宫素可能是最有效的单药预防方案。缩宫素联合麦角新碱、米索前列醇、卡前列素等二线宫缩剂具有相加或协同效应,较单用缩宫素可更大程度降低产后出血风险,因此应推荐联合治疗而非单用缩宫素预防产后出血。氨甲环酸可有效且安全地降低产后出血患者的孕产妇死亡,预防性使用可能减少浓缩红细胞输注和/或宫缩剂需求。

要点

  • 缩宫素是美国预防产后出血的一线宫缩剂,证据充分。
  • 卡贝缩宫素可能是最有效的单药药物预防方案,可减少额外宫缩剂需求。
  • 缩宫素联合麦角新碱、米索前列醇或卡前列素具有相加或协同效应,较单用缩宫素降低产后出血风险更显著。

核心结论

  • 应推荐联合治疗而非单用缩宫素预防产后出血。
  • 氨甲环酸可有效且安全地降低产后出血患者的孕产妇死亡,预防性使用可能减少浓缩红细胞输注和/或宫缩剂需求。

研究设计与样本

  • 本文为综述,汇总产后出血药物预防的单药与联合治疗证据。

主要发现

  • 宫缩乏力约占产后出血病例的70%至80%。
  • 缩宫素是美国预防产后出血的一线宫缩剂,证据充分。
  • 卡贝缩宫素为长效缩宫素类似物,在美国尚未上市,但可能是预防产后出血及减少额外宫缩剂需求的最有效单药药物方案。
  • 缩宫素联合麦角新碱、米索前列醇、卡前列素等二线宫缩剂具有相加或协同效应,较单用缩宫素可更大程度降低产后出血风险。
  • 氨甲环酸可有效且安全地降低产后出血患者的孕产妇死亡,预防性使用可能减少浓缩红细胞输注和/或宫缩剂需求。

临床怎么用

  • 作者建议预防产后出血应采用联合治疗而非单用缩宫素。
  • 缩宫素是美国预防产后出血的一线宫缩剂。
  • 卡贝缩宫素在美国尚未上市,但可能是最有效的单药药物预防方案。
  • 缩宫素联合二线宫缩剂较单用缩宫素可更大程度降低产后出血风险。
  • 氨甲环酸预防性使用可能减少浓缩红细胞输注和/或宫缩剂需求。

局限性

  • 缩宫素与其他二线治疗联合的相加、次相加或协同作用值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Postpartum hemorrhage is the leading cause of maternal morbidity and mortality worldwide, with uterine atony estimated to account for 70% to 80% of cases, thereby remaining the single most common cause. Pharmacotherapy remains the first-line preventative therapy for postpartum hemorrhage. These therapies may be single (oxytocin, carbetocin, methylergonovine, ergometrine, misoprostol, prostaglandin analogs, or tranexamic acid) or combination therapies, acting in an additive, infra-additive, or synergistic fashion to prevent postpartum hemorrhage. Evidence is strong for the use of oxytocin, the first-line uterotonic agent in the United States for prevention of postpartum hemorrhage. Although carbetocin, a long-acting analog of oxytocin, is not yet available for use in the United States, it is likely the most effective single pharmacologic therapy for prevention of postpartum hemorrhage and need for additional uterotonics. Use of second-line uterotonics such as methylergonovine, misoprostol, and carboprost in combination with oxytocin has an additive or synergistic effect and a greater risk reduction for postpartum hemorrhage prevention compared with oxytocin alone. Therefore, combined therapy rather than oxytocin alone should be advised for preventing postpartum hemorrhage. Tranexamic acid has been found to be both effective and safe for decreasing maternal mortality in women with postpartum hemorrhage, and prophylactic use of tranexamic acid may decrease the need for packed red blood cell transfusions and/or uterotonics. The WOMAN-2 Trial, designed to assess if tranexamic acid prevents postpartum hemorrhage in women with moderate to severe anemia undergoing vaginal delivery, is currently recruiting participants. The additive, infra-additive, or synergistic action of oxytocin in combination with other second-line therapies deserves further study.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Jones AJ, Federspiel JJ, Eke AC, et al. Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone. Am J Obstet Gynecol MFM. 2022. PMID: 36028160. doi:10.1016/j.ajogmf.2022.100731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。